Ronda Stryker's "24% stake cut" is 3.6% — and the three 2026 sales are priced in dollars, not shares
On 6 November 2026 she sold 550,000 SYK shares at $325.32 — $178,924,731 — as an open-market sale (code S) from an indirect account, leaving 1,701,375 shares on that reporting line. Form 4 filed 9 November at 16:29 ET. Her 2026 record, read across filings:
| Date | Action | Shares | Price | Value |
|---|---|---|---|---|
| 14 Jan 2026 | Option exercise | 4,570 | — | — |
| 2 Feb 2026 | Gift | 655,800 | — | — |
| 4 Feb 2026 | Transfer | 42,000 | — | — |
| 4–5 Feb 2026 | Sale | 500,000 | $358.51–$368.56 | $181.7m |
| 26 May 2026 | Sale (Revocable Trust) | 310,000 | $310.77–$315.11 | ≈$96.8m |
| 6 Nov 2026 | Sale | 550,000 | $325.32 | $178.9m |
| Sales, 10 months | 1,360,000 | ≈$457m |
Her Schedule 13D/A filed 14 April 2026 reports beneficial ownership of 15,223,331 shares — 4.0% of the class — of which 2,235,338 carry sole voting and dispositive power and 12,987,993 shared, spread across a revocable trust, the L. Lee Stryker Trust (13,578,805 after the February activity), the 1988 William D. Johnston Trust (37,600), a family foundation on which she is one of several trustees voting by majority, and shares held by her husband. The 13D/A expressly reserves the right to dispose by sale, including Rule 144 sales, by gift, by transfer, or by letting options lapse.
Form 4, Stryker Corp, reporting person Stryker Ronda E, transaction 6 Nov 2026, filed 9 Nov 2026 16:29 ET · Form 4, transaction 26 May 2026, filed 28 May 2026 17:22 ET (Revocable Trust; footnote records 679,642 shares transferred in from the L. Lee Stryker Trust on 28 May) · Form 4, transactions 4–5 Feb 2026 · SC 13D/A, Stryker Corp, filed 14 Apr 2026, event date 27–28 Feb 2026
A founding-family director sells $179m and cuts her stake 24% — the largest insider disposal at Stryker this year, filed three days after the trade, with no trading plan indicated. The family that built the company is stepping back from it, and the natural inference is a view on valuation after a long run in medtech.
The 24% is an artifact of which entity line the filing happens to report, and against her actual position the sale is about 3.6%. The three 2026 sales are not price decisions at all: they hold dollars roughly constant while share counts move with price. The one genuinely interesting thing in the filing is the one nobody is quoting — the absent 10b5-1 checkbox.
- The denominator is not a choice variable. Her own 13D/A puts beneficial ownership at 15,223,331 shares, 4.0% of the class. A 550,000-share sale is 3.6% of that. The "24%" is 550,000 divided by the roughly 2,251,375 that happened to sit in one indirect line before the trade. Which line a share sits in is an administrative fact about trust structure, not a statement about conviction — and Form 4 reports per line. The headline is measuring the wrong thing, and it is measuring it against a number she controls.
- She sold MORE shares at a LOWER price, for nearly the same money. February: 500,000 shares at $358.51–$368.56 for $181.7m. November: 550,000 shares at $325.32 for $178.9m. Share count +10%, price −11%, proceeds −1.5%. That is a dollar-targeted programme, and it is the mathematical opposite of a price-driven decision: a seller reacting to a lower price sells fewer shares or none, while a seller funding a fixed obligation sells more. This is the crux and it is arithmetic, not interpretation.
- February proves the programme is not only selling. In the same four-day window she gifted 655,800 shares and transferred 42,000 alongside the 500,000-share sale. A person losing confidence sells. A person executing an estate and philanthropy plan sells, gifts and transfers together — which is precisely what her 13D/A says she reserves the right to do.
- The cadence was already established before November. February, May, November: three tranches in ten months, roughly quarterly-to-four-monthly, 1,360,000 shares and about $457m. The November trade is the third instance of a pattern, not a departure from one.
The cleanest falsifier is a fourth sale in the next ninety days sized in shares rather than dollars — if the next tranche is another 550,000 at whatever price, the dollar-targeting claim is dead and these are three unrelated discretionary sales that happened to land near $180m twice by coincidence. Separately: if the 26 May tranche's true proceeds are materially different from the ~$96.8m I am working from once the six weighted-average prices are properly weighted, the middle data point weakens and the two-point February–November fit is thinner than it looks. And if the Form 4 turns out to carry a checked 10b5-1 box after all, the schedule reading strengthens but the anomaly flag at the top of this edition should be withdrawn.
Three sales in 2026 at roughly $180m, $97m and $179m. Holdings after February: Revocable Trust 2,207,331; L. Lee Stryker Trust 13,578,805; 1988 William D. Johnston Trust 37,600; direct 560. The May filing's footnote shows 679,642 shares moving into the Revocable Trust from the L. Lee Stryker Trust on 28 May — i.e. the selling account is being refilled from the generational trust between tranches. That is the mechanical signature of a funded disposition programme, and it is also exactly why the per-line "stake cut" percentage is meaningless: the line is a conduit, not a position.